Functionalization Process for Commercial Viability: Oral Leukoplakia Detection Using IL-6 Biomarker

被引:0
|
作者
Wan, Hsiao-Hsuan [1 ]
Zhu, Haochen [1 ]
Chiang, Chao-Ching [1 ]
Xia, Xinyi [1 ]
Li, Jian-Sian [1 ]
Ren, Fan [1 ]
Tsai, Cheng-Tse [2 ]
Liao, Yu-Te [2 ]
Chou, Tai-Cheng [3 ]
Neal, Dan [4 ]
Katz, Joseph [5 ]
Esquivel-Upshaw, Josephine F. [6 ]
机构
[1] Univ Florida, Dept Chem Engn, Gainesville, FL 32611 USA
[2] Natl Yang Ming Chiao Tung Univ, Dept Elect & Elect Engn, Hsinchu 30010, Taiwan
[3] TaiDoc Technol Corp, New Taipei City 24888, Taiwan
[4] Univ Florida, Dept Surg, Gainesville, FL 32611 USA
[5] Univ Florida, Dept Oral & Maxillofacial Diagnost Sci, Gainesville, FL 32611 USA
[6] Univ Florida, Dept Restorat Dent Sci, Div Prosthodont, Gainesville, FL 32611 USA
关键词
oral cancer; biomarkers; IL-6; oral leukoplakia; biosensor; NECROSIS-FACTOR-ALPHA; SALIVARY INTERLEUKIN-6; BETEL QUID; CANCER; ALCOHOL; RISK; PRECANCER; DIAGNOSIS; BIOSENSOR; TOBACCO;
D O I
10.1149/2162-8777/ad6eb6
中图分类号
T [工业技术];
学科分类号
08 ;
摘要
Oral leukoplakia (OL) or white patched in the oral cavity poses a diagnostic challenge in oral health due to its white patches on the oral mucosa, affecting 1%-2% of the population, predominantly those over 40 years old. Despite being often benign, OL often precedes potentially malignant disorders and oral cancer, necessitating early detection and intervention. The search for novel biomarkers has intensified, with interleukin-6 (IL-6) emerging as a promising candidate. IL-6 detection levels in saliva offer a non-invasive approach, aiding an accurate risk assessment and treatment planning. Here, we introduce an IL-6-based biosensor for rapid concentration detection. A novel, hour-long functionalization method streamlines mass production, maintaining a low detection limit down to 10-15 g ml-1, which is three order lower than current commercial ELISA kits, with a sensitivity around 18/dec. Utilizing a specially designed printed circuit board with double pulse technology ensures precise concentration results, with human sample tests confirming the biosensor's efficacy in real-world applications. This innovation represents a significant advancement in early OL detection, enabling timely intervention to prevent its progression to more severe forms of oral cancer.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] IL-6 as a Biomarker for Lymphedema
    Weitman, E.
    Zampell, J.
    Aschen, S.
    Farias-Eisner, G.
    Cuzzone, D.
    Ghanta, S.
    Albano, N.
    Rockson, S.
    Mehrara, B. J.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S51 - S51
  • [2] IL-6 Quotient (The Ratio of Cerebrospinal Fluid IL-6 to Serum IL-6) as a Biomarker of an Unruptured Intracranial Aneurysm
    Kaminska, Joanna
    Dymicka-Piekarska, Violetta
    Chrzanowski, Robert
    Sawicki, Karol
    Milewska, Anna J.
    Zinczuk, Justyna
    Tylicka, Marzena
    Jadeszko, Marek
    Mariak, Zenon
    Kratz, Ewa M.
    Matowicka-Karna, Joanna
    Kornhuber, Johannes
    Lewczuk, Piotr
    Koper-Lenkiewicz, Olga M.
    JOURNAL OF INFLAMMATION RESEARCH, 2021, 14 : 6103 - 6114
  • [3] Salivary IL-6 mRNA is a Robust Biomarker in Oral Squamous Cell Carcinoma
    Marton, Ildiko Judit
    Horvath, Jozsef
    Labiscsak, Peter
    Markus, Bernadett
    Dezso, Balazs
    Szabo, Adrienn
    Tar, Ildiko
    Piffko, Jozsef
    Jakus, Petra
    Barabas, Jozsef
    Barabas, Peter
    Olasz, Lajos
    Kover, Zsanett
    Tozser, Jozsef
    Sandor, Janos
    Csosz, Eva
    Scholtz, Beata
    Kiss, Csongor
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (11)
  • [4] Salivary IL-6 levels in oral leukoplakia with dysplasia and its clinical relevance to tobacco habits and periodontitis
    Sharma, Mohit
    Bairy, Indira
    Pai, Keerthilatha
    Satyamoorthy, Kapaettu
    Prasad, Shailendra
    Berkovitz, Barry
    Radhakrishnan, Raghu
    CLINICAL ORAL INVESTIGATIONS, 2011, 15 (05) : 705 - 714
  • [5] Salivary IL-6 levels in oral leukoplakia with dysplasia and its clinical relevance to tobacco habits and periodontitis
    Mohit Sharma
    Indira Bairy
    Keerthilatha Pai
    Kapaettu Satyamoorthy
    Shailendra Prasad
    Barry Berkovitz
    Raghu Radhakrishnan
    Clinical Oral Investigations, 2011, 15 : 705 - 714
  • [6] IL-6 as a potential biomarker in lung cancer
    Yeh, Yu-Min
    Su, Wu-Chou
    LUNG CANCER MANAGEMENT, 2014, 3 (03) : 237 - 240
  • [7] Serum IL-6: A biomarker in childhood asthma?
    Jackson, Daniel J.
    Bacharier, Leonard B.
    Calatroni, Agustin
    Gill, Michelle A.
    Hu, Jack
    Liu, Andrew H.
    Wheatley, Lisa M.
    Gem, James E.
    Gruchalla, Rebecca S.
    Hershey, Gurjit K. Khurana
    Kattan, Meyer
    Kercsmar, Carolyn M.
    Kim, Haejin
    O'Connor, George T.
    Patel, Shilpa
    Pongracic, Jacqueline A.
    Wood, Robert A.
    Busse, William W.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (06) : 1701 - +
  • [8] IL-6 as a biomarker of ischemic cerebrovascular disease
    Moreno, Vanessa P.
    Subira, Dolores
    Meseguer, Elena
    Llamas, Pilar
    BIOMARKERS IN MEDICINE, 2008, 2 (02) : 125 - 136
  • [9] Ultrasensitive Electrochemical Immunosensor for Oral Cancer Biomarker IL-6 Using Carbon Nanotube Forest Electrodes and Multilabel Amplification
    Malhotra, Ruchika
    Patel, Vyomesh
    Vaque, Jose Pedro
    Gutkind, J. Silvio
    Rusling, James F.
    ANALYTICAL CHEMISTRY, 2010, 82 (08) : 3118 - 3123
  • [10] The Combination of IL-6 and IL-6 Receptor Levels As a Biomarker of Response to Tocilizumab in Rheumatoid Arthritis Patients
    Diaz-Torne, Cesar
    Ortiz, Maria A.
    Moya, Patricia
    Victoria Hernandez, M.
    Reina, Delia
    Castellvi, Ivan
    Jose De Agustin, Juan
    De La Fuente, Diana
    Corominas, Hector
    Sanmarti, Raimon
    De Llobet Zubiaga, Josep Maria
    Vidal, Silvia
    ARTHRITIS & RHEUMATOLOGY, 2016, 68